EP1309603A4 - NUCLEIC ACIDS COMPRISING PEG-3 PROMOTER REGIONS OF RAT AND USES THEREOF - Google Patents

NUCLEIC ACIDS COMPRISING PEG-3 PROMOTER REGIONS OF RAT AND USES THEREOF

Info

Publication number
EP1309603A4
EP1309603A4 EP01954874A EP01954874A EP1309603A4 EP 1309603 A4 EP1309603 A4 EP 1309603A4 EP 01954874 A EP01954874 A EP 01954874A EP 01954874 A EP01954874 A EP 01954874A EP 1309603 A4 EP1309603 A4 EP 1309603A4
Authority
EP
European Patent Office
Prior art keywords
promotor
peg
nucleic acids
containing nucleic
rats containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01954874A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1309603A1 (en
Inventor
Paul B Fisher
Zao-Zhong Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/621,781 external-priority patent/US6737523B1/en
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP1309603A1 publication Critical patent/EP1309603A1/en
Publication of EP1309603A4 publication Critical patent/EP1309603A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP01954874A 2000-07-21 2001-07-20 NUCLEIC ACIDS COMPRISING PEG-3 PROMOTER REGIONS OF RAT AND USES THEREOF Withdrawn EP1309603A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US621781 1984-06-18
US09/621,781 US6737523B1 (en) 1998-03-20 2000-07-21 Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
PCT/US2001/023099 WO2002008242A1 (en) 2000-07-21 2001-07-20 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof

Publications (2)

Publication Number Publication Date
EP1309603A1 EP1309603A1 (en) 2003-05-14
EP1309603A4 true EP1309603A4 (en) 2004-07-28

Family

ID=24491606

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01954874A Withdrawn EP1309603A4 (en) 2000-07-21 2001-07-20 NUCLEIC ACIDS COMPRISING PEG-3 PROMOTER REGIONS OF RAT AND USES THEREOF

Country Status (5)

Country Link
EP (1) EP1309603A4 (ja)
JP (1) JP2004520006A (ja)
AU (1) AU2001277094A1 (ja)
CA (1) CA2416676A1 (ja)
WO (1) WO2002008242A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500910A (ja) 2002-04-18 2006-01-12 アキュイティ ファーマシューティカルズ、インク． Ｃｎｓと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7449565B2 (en) 2005-01-21 2008-11-11 The Trustees Of Columbia University In The City Of New York Chimeric tumor suppressor gene and protein
EP2361306A1 (en) 2008-12-04 2011-08-31 OPKO Ophthalmics, LLC Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
EP2633063A4 (en) * 2010-10-28 2015-11-04 Univ Virginia Commonwealth CANCER IMAGING USING THERAPY: THE THERANOSTIC

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049898A1 (en) * 1998-03-31 1999-10-07 The Trustees Of Columbia University In The City Of New York Progression elevated gene-3 and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049898A1 (en) * 1998-03-31 1999-10-07 The Trustees Of Columbia University In The City Of New York Progression elevated gene-3 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 9 April 2001 (2001-04-09), XP002281485, retrieved from EBI Database accession no. AF351130 *
MILAS MIRA ET AL: "Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity", CANCER GENE THERAPY, vol. 7, no. 3, March 2000 (2000-03-01), pages 422 - 429, XP002281484, ISSN: 0929-1903 *
See also references of WO0208242A1 *
SU ZAO-ZHONG ET AL: "Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells", ONCOGENE, vol. 19, no. 30, 13 July 2000 (2000-07-13), pages 3411 - 3421, XP002281483, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2001277094A1 (en) 2002-02-05
EP1309603A1 (en) 2003-05-14
JP2004520006A (ja) 2004-07-08
WO2002008242A1 (en) 2002-01-31
CA2416676A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
SG94863A1 (en) Stabilizing rhodium catalysts for the hydroformylation of olefins
DE60137675D1 (de) Gerät zur Unterstützung nach der Geburt
GB0015129D0 (en) Processor for FIR filtering
DE60128186D1 (de) Abgasreinigungskatalysator
DE50105494D1 (de) Filterelement zur stirnseitigen anströmung
AR028414A1 (es) Compuestos quimicos
DE60122243D1 (de) Abgasreinigungskatalysator
DE60144321D1 (de) Abgasreinigungskatalysator
DK1326832T3 (da) Kemiske forbindelser
DE60138513D1 (de) Abgasreinigungskatalysator
DE60119664D1 (de) Kabelbaum
DE60138984D1 (de) Abgasreinigungskatalysator
NO20035358D0 (no) Somatostatin-dopamin chimere analoger
EE200200564A (et) Stavudiini sisaldavad toimeainet aeglustatult vabastavad graanulid
ATE364017T1 (de) Geschirr zum füttern von kindern
DK1157616T3 (da) Foderstof til husdyr
ATE309983T1 (de) Beta-thio-aminosäuren
EP1309603A4 (en) NUCLEIC ACIDS COMPRISING PEG-3 PROMOTER REGIONS OF RAT AND USES THEREOF
IT250181Y1 (it) Custodia perfezionata per rivoltella
DE60110856D1 (de) Anschlussklemme zur Verbindung von Stützenelementen
ATE331046T1 (de) Magnesium enthaltendes entschwefelungsmittel
GB0108104D0 (en) Probes for myctophid fish
DE60126023D1 (de) System zur Durchführung sequentieller Reaktionen
DE60107637D1 (de) Kabelbaum
IT1318186B1 (it) Apparato di filtraggio per lavastoviglie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030213

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040614

17Q First examination report despatched

Effective date: 20070813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090201